Bashar Al-Sheklly
Impact in
- Infectious Diseases top 0.5%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Neurology top 1%
- Long-Term Effects of COVID-19
Papers in
- Neurology 13
- Long-Term Effects of COVID-19 13
-
- COVID-19 Clinical Research Studies 14
- SARS-CoV-2 and COVID-19 Research 2
- Co-authors
- Imran Satia (7 shared papers)Huda Badri (5 shared papers)John A. Smith (8 shared papers)Ashley A. Woodcock (3 shared papers)Rachel Dockry (6 shared papers)Kimberley Holt (6 shared papers)Basil George Issa (2 shared papers)Douglas R. Corfield (2 shared papers)
- Journals
- The Lancet (7 papers)The Lancet Respiratory Medicine (5 papers)EClinicalMedicine (3 papers)EBioMedicine (2 papers)Respiratory Medicine (1 paper)
- Partner nations
- United KingdomCanadaUnited States
In The Last Decade
Bashar Al-Sheklly
39 papers receiving 4.3k citations
Bashar Al-Sheklly's Hit Papers
Peers
Comparison fields: 5 of 114
- Infectious Diseases 2.6k
- Neurology 906
- Applied Microbiology and Biotechnology 40
- Internal Medicine 31
- Pulmonary and Respiratory Medicine 278
Countries citing papers authored by Bashar Al-Sheklly
This map shows the geographic impact of Bashar Al-Sheklly's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bashar Al-Sheklly with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bashar Al-Sheklly more than expected).
Fields of papers citing papers by Bashar Al-Sheklly
This network shows the impact of papers produced by Bashar Al-Sheklly. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bashar Al-Sheklly. The network helps show where Bashar Al-Sheklly may publish in the future.
Co-authors
The 25 scholars most cited alongside Bashar Al-Sheklly, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 41 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 1531 |
| 2 | Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study Hit paper breakdown → | 2021 | 504 |
| 3 | Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 411 |
| 4 | Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial Hit paper breakdown → | 2021 | 393 |
| 5 | Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study Hit paper breakdown → | 2022 | 310 |
| 6 | Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2022 | 282 |
| 7 | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis Hit paper breakdown → | 2022 | 231 |
| 8 | 2021 | 213 | |
| 9 | 2022 | 87 | |
| 10 | Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2023 | 84 |
| 11 | Large-scale phenotyping of patients with long COVID post-hospitalization reveals mechanistic subtypes of disease Hit paper breakdown → | 2024 | 65 |
| 12 | 2016 | 35 | |
| 13 | 2023 | 35 | |
| 14 | 2024 | 31 | |
| 15 | 2023 | 25 | |
| 16 | 2024 | 24 | |
| 17 | 2023 | 22 | |
| 18 | 2022 | 21 | |
| 19 | 2017 | 17 | |
| 20 | 2023 | 17 |
About Bashar Al-Sheklly
Bashar Al-Sheklly is a scholar working on Neurology, Infectious Diseases, Pulmonary and Respiratory Medicine, Geriatrics and Gerontology and Physiology, having authored 41 papers that have together received 4.5k indexed citations. Recurring topics across this work include COVID-19 Clinical Research Studies (14 papers), Long-Term Effects of COVID-19 (13 papers), Respiratory and Cough-Related Research (12 papers), SARS-CoV-2 and COVID-19 Research (2 papers), Asthma and respiratory diseases (2 papers), Sleep and related disorders (1 paper), Frailty in Older Adults (1 paper) and Kawasaki Disease and Coronary Complications (1 paper). The work is most often cited by research in Infectious Diseases (2.6k citations), Neurology (906 citations), Applied Microbiology and Biotechnology (40 citations), Internal Medicine (31 citations) and Pulmonary and Respiratory Medicine (278 citations). Bashar Al-Sheklly has collaborated with scholars based in United Kingdom, Canada and United States. Frequent co-authors include Imran Satia, Huda Badri, John A. Smith, Ashley A. Woodcock, Rachel Dockry, Kimberley Holt, Basil George Issa, Douglas R. Corfield, Stephen J. Fowler and Robert McL. Niven. Their work appears in journals such as The Lancet, The Lancet Respiratory Medicine, EClinicalMedicine, EBioMedicine and Respiratory Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.